WuXi STA and BioLingus sign exclusive partnership
Shanghai and San diego, February 20, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec – and BioLingus, a Swiss biotech company, announce they have formed an exclusive technology and marketing collaboration for sublingual delivery.
Under the terms of the collaboration, WuXi STA will have exclusive access to BioLingus technology for sublingual and buccal delivery in the contract development and manufacturing organization (CDMO) sector. BioLingus has developed a novel platform – with patents secured in major countries around the world – to stabilize and deliver sublingually (orally under the tongue) drug targets including small molecules, peptides and proteins, that are currently administered to patients via injection.
The collaboration will help further integrate the advantages of WuXi STA drug product services and expedite the development of BioLingus’ pipeline and usage of sublingual delivery technology.
In 2017, WuXi STA merged with